SCHEMBL682591

SCHEMBL682591

O=C(Cc1ccccc1)c1ccc(F)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.67
MAPT P10636 1/20 0.67
SRD5A2 P31213 2/20 0.65
ALDH1A1 P00352 3/20 0.58
RAB9A P51151 6/20 0.57
SMN1; SMN2 Q16637 2/20 0.55
LMNA P02545 1/20 0.55
MAPK1 P28482 1/20 0.55
CASP3 P42574 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
HSD11B1 P28845 2/20 0.54
STS P08842 1/20 0.54
NPC1 O15118 4/20 0.53
PTPN1 P18031 1/20 0.53
CNR2 P34972 1/20 0.51
PLAU P00749 1/20 0.50
KDM4E B2RXH2 1/20 0.50
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL71493 0.92 L3MBTL1 (0.56) L3MBTL1MAPTSRD5A2ALDH1A1RAB9A
SCHEMBL6201900 0.90 RAB9A (0.59) L3MBTL1MAPTSRD5A2RAB9ASMN1; SMN2
SCHEMBL7129800 0.89 MAPT (0.80) L3MBTL1MAPTSRD5A2RAB9ASMN1; SMN2
SCHEMBL7167952 0.86 SRD5A2 (0.62) L3MBTL1MAPTSRD5A2ALDH1A1RAB9A
SCHEMBL24800 0.85 MAPT (0.73) L3MBTL1MAPTSRD5A2ALDH1A1RAB9A
SCHEMBL8956299 0.85 SRD5A2 (0.60) L3MBTL1MAPTSRD5A2RAB9ALMNA
SCHEMBL13052378 0.85 MAPK1 (0.53) L3MBTL1MAPTSRD5A2ALDH1A1RAB9A
SCHEMBL10767044 0.85 MEN1 (0.60) L3MBTL1MAPTSRD5A2ALDH1A1RAB9A
SCHEMBL10767038 0.85 SRD5A2 (0.60) L3MBTL1MAPTSRD5A2RAB9ALMNA
SCHEMBL5260372 0.83 SRD5A2 (0.89) L3MBTL1MAPTSRD5A2RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114230447-B Continuous flow preparation method of 4' -fluoro-2-phenyl acetophenone 河南豫辰药业股份有限公司 2024-06-21 CN claimed
CN-117695992-A Full-continuous chemical synthesis device and method for atorvastatin calcium mother nucleus 复旦大学 2024-03-15 CN claimed
CN-113755862-B Method for preparing aromatic alpha-diketone compound by electrochemical oxidation 西南大学 2022-08-19 CN claimed
CN-111170856-B Preparation method and application of fluoroolefin 云南民族大学 2022-04-15 CN claimed
CN-114230447-A Continuous flow preparation method of 4' -fluoro-2-phenylacetophenone 河南豫辰药业股份有限公司 2022-03-25 CN claimed
CN-113755862-A Method for preparing aromatic alpha-diketone compound by electrochemical oxidation 西南大学 2021-12-07 CN claimed
CN-103724175-A Synthetic method of atorvastatin intermediate alpha-bromine-4-fluorophenyl benzyl ketone ANQING JINQUAN PHARM CO LTD 2014-04-16 CN claimed
CN-101307009-A New synthetic method for (earth)4-fluor-alpha-(2-methyl-1-oxypropyl )-gamma-oxo-N, beta-diphenyl benzene butanamide ZHEJIANG JINGXIN PHARMACEUTICA (CN) 2008-11-19 CN claimed
CN-119936244-A Method for detecting aldehyde genotoxic impurities in atorvastatin calcium 华北制药集团新药研究开发有限责任公司 2025-05-06 CN disclosed
CN-118908819-B Preparation method of organic ketone compound under synergistic catalysis of light and metal 延安大学 2025-04-18 CN disclosed
CN-119318997-B Magnetic resin immobilized ionic liquid heteropolyacid catalyst and preparation method and application thereof 浙江先锋科技集团股份有限公司 2025-04-01 CN disclosed
CN-119318997-A Magnetic resin immobilized ionic liquid heteropolyacid catalyst and preparation method and application thereof 浙江先锋科技集团股份有限公司 2025-01-17 CN disclosed
CN-118908819-A Preparation method of organic ketone compound under synergistic catalysis of light and metal 延安大学 2024-11-08 CN disclosed
CN-114230447-B Continuous flow preparation method of 4' -fluoro-2-phenyl acetophenone 河南豫辰药业股份有限公司 2024-06-21 CN disclosed
US-20020086886-A1 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors G.D. SEARLE & CO. 2002-07-04 US disclosed
EP-0995747-A1 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors G.D. SEARLE & CO. (US) 2000-04-26 EP disclosed
WO-1996036617-A1 SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-11-21 WO disclosed
EP-0006254-B1 BENZOIN OXIME DERIVATIVES, PROCESS FOR THEIR PREPARATION, COMPOSITIONS CONTAINING SUCH DERIVATIVES AND METHOD FOR THEIR USE AS FUNGICIDES SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1982-12-22 EP disclosed
US-4304789-A Benzoin oxime fungicides SHELL OIL COMPANY (US) 1981-12-08 US disclosed
EP-0006254-A1 Benzoin oxime derivatives, process for their preparation, compositions containing such derivatives and method for their use as fungicides SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1980-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086886-A1 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors ALOX5, PTGES2, PTGS2 L3MBTL1 3843/4885MAPT 4859/4885SRD5A2 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.